Instituto Nacional de Cancer

Rio de Janeiro 20560-120

1 studies enrolling now · 8 studies all time

What they study most

AML Arising From Myelodysplastic Syndrome (MDS), Advanced Breast Cancer, Advanced Solid Tumor, Autologous Stem Cell Transplant, Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone-receptor-positive Breast Cancer

Studies at this site

• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — Recruiting now
• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation — Running, not enrolling
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant — Completed
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) — Completed
• Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer — Completed
• Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer — Completed
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — Completed